Literature DB >> 22876544

Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.

Eric T Rush1, Kristi DeHaai, Rose M Kreikemeier, Richard E Lutz.   

Abstract

The use of bisphosphonates in children to treat low bone mineral density has increased. Safety and efficacy of pamidronate has been previously demonstrated. However, little research has been done on pamidronate infusion in the home health setting for patients with metabolic bone disease. Data were collected via a survey to assess satisfaction and convenience of infusions. Adverse events were measured by collecting calcium levels before and after infusions. Infusion costs were estimated from the standard orders from one home health agency and our infusion center. We found no difference in the rates of hypocalcemia between the two groups. The survey results showed high satisfaction for both groups, with higher scores in the home health group for convenience and stress. Home health infusions showed lower cost and less absenteeism from school and work. Home health-based pamidronate infusion appears to be safe, less expensive, and is associated with high patient satisfaction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22876544     DOI: 10.1515/jpem-2011-0498

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  2 in total

1.  Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study.

Authors:  Evelina Maines; Elisa Tadiotto; Grazia Morandi; Michela Fedrizzi; Rossella Gaudino; Paolo Cavarzere; Alessandra Guzzo; Franco Antoniazzi
Journal:  J Pediatr Genet       Date:  2020-01-06

2.  Cardiovascular involvement in children with osteogenesis imperfecta.

Authors:  Hamdollah Karamifar; Homa Ilkhanipoor; Gholamhossein Ajami; Zohreh Karamizadeh; Gholamhossein Amirhakimi; Ali-Mohammad Shakiba
Journal:  Iran J Pediatr       Date:  2013-10       Impact factor: 0.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.